| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1452 | 2019 |
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ... The Lancet 379 (9829), 1893-1901, 2012 | 1053 | 2012 |
| Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study T Powles, PH O'Donnell, C Massard, HT Arkenau, TW Friedlander, ... JAMA oncology 3 (9), e172411-e172411, 2017 | 942 | 2017 |
| Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study LY Dirix, I Takacs, G Jerusalem, P Nikolinakos, HT Arkenau, ... Breast cancer research and treatment 167, 671-686, 2018 | 826 | 2018 |
| Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial K Shitara, T Doi, M Dvorkin, W Mansoor, HT Arkenau, A Prokharau, ... The Lancet Oncology 19 (11), 1437-1448, 2018 | 503 | 2018 |
| Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE … MA Shah, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, ... JAMA oncology 5 (4), 546-550, 2019 | 487 | 2019 |
| Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020 | 477 | 2020 |
| Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and … J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ... Journal of Clinical Oncology 39 (4), 273-284, 2021 | 452 | 2021 |
| Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO … R Porschen, HT Arkenau, S Kubicka, R Greil, T Seufferlein, W Freier, ... Journal of Clinical Oncology 25 (27), 4217-4223, 2007 | 379 | 2007 |
| Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. R Kefford, H Arkenau, MP Brown, M Millward, JR Infante, GV Long, ... Journal of Clinical Oncology 28 (15_suppl), 8503-8503, 2010 | 355 | 2010 |
| Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience D Olmos, HT Arkenau, JE Ang, I Ledaki, G Attard, CP Carden, AHM Reid, ... Annals of oncology 20 (1), 27-33, 2009 | 304 | 2009 |
| Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a … RS Herbst, HT Arkenau, R Santana-Davila, E Calvo, L Paz-Ares, ... The Lancet Oncology 20 (8), 1109-1123, 2019 | 266 | 2019 |
| Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials HT Arkenau, D Arnold, J Cassidy, E Diaz-Rubio, JY Douillard, H Hochster, ... Journal of Clinical Oncology 26 (36), 5910-5917, 2008 | 235 | 2008 |
| A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors S Pacey, RH Wilson, M Walton, MM Eatock, A Hardcastle, A Zetterlund, ... Clinical cancer research 17 (6), 1561-1570, 2011 | 231 | 2011 |
| Prospective validation of a prognostic score to improve patient selection for oncology phase I trials HT Arkenau, J Barriuso, D Olmos, JE Ang, J de Bono, I Judson, S Kaye Journal of clinical oncology 27 (16), 2692-2696, 2009 | 225 | 2009 |
| Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study L Shen, K Kato, SB Kim, JA Ajani, K Zhao, Z He, X Yu, Y Shu, Q Luo, ... Journal of clinical oncology 40 (26), 3065-3076, 2022 | 220* | 2022 |
| Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study F Meric-Bernstam, R Bahleda, C Hierro, M Sanson, J Bridgewater, ... Cancer discovery 12 (2), 402-415, 2022 | 207 | 2022 |
| Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436) KL Nathanson, AM Martin, B Wubbenhorst, J Greshock, R Letrero, ... Clinical cancer research 19 (17), 4868-4878, 2013 | 206 | 2013 |
| Targeting BRAF for patients with melanoma HT Arkenau, R Kefford, GV Long British journal of cancer 104 (3), 392-398, 2011 | 197 | 2011 |
| Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial JS De Bono, N Concin, DS Hong, FC Thistlethwaite, JP Machiels, ... The Lancet Oncology 20 (3), 383-393, 2019 | 195 | 2019 |
